Hydrocortisone in Severe Community-Acquired Pneumonia
Compared with placebo, hydrocortisone reduced the 28-day mortality risk among critically ill patients with severe community-acquired pneumonia, according to results of the Community-Acquired Pneumonia: Evaluation